Mayo Center for Cell Signaling in Gastroenterology

项目总结 梅奥临床胃肠病细胞信号中心(C-SIG)的总体目标是利用 胃肠道细胞中的信号通路以改善消化系统疾病患者的健康。要做到这点， C-SIG提供强大的基础设施、主题平台和职业发展机会，以整合 并沿着发现-翻译-应用范式放大有影响力的调查。我们的研究基地 现在有68名科学家(增长15%)，涉及18个部门和2370万美元(直接成本， 2.5%的增长)与消化疾病相关的资金。回应成员不断发展的兴趣和科学 进展，我们已将成员重新调整为三个相互关联的力学研究主题(细胞内 信号传递、细胞间通讯和遗传学/表观遗传学)，每一种都与三种疾病交叉 焦点小组(肝脏病理生物学、肠道神经科学、炎症/转化)， 促进发现和疾病相关调查。我们正在进行的中心假设是 消化疾病患者护理的进步需要有意义的促进性基础设施 研究细胞机制、途径和治疗的多学科科学家之间的相互作用 目标是加强将基本发现快速转化为临床试验。我们的总体具体目标是 到：i)通过扩大现有的技术和协作能力，促进多学科研究 GI科学家和吸引其他学科的研究人员；二)确定和培养新的GI研究人员 通过同行评审的试点和可行性(P/F)计划，包括职业发展研讨会、课程、 和结构化指导(19/26，73%的P/F接受者获得联邦资助)；iii)提供以核心为基础的 专门的设备、技术、方法、试剂和专业知识(光学显微镜、临床、 以及基因编辑和表观基因组学核心)，具有持续的核心菜单更新、质量保证和 响应成员反馈的评估和项目管理监督；四)支持强有力的 浓缩计划；以及v)促进C-Sig与Mayo的其他NIDDK中心之间的互动(例如， PKD中心)和现有的复员方案协调中心，特别是在中西部(即中西部复员方案协调中心联盟)。我们的全球 努力的结果是215份手稿，其中56%是主题内出版物，44%是主题间出版物 (70%涉及两名或以上成员)。重要的是，我们在理解疾病方面取得了重大进展 发病机制与信号转导、细胞间通讯和遗传学/表观遗传学有关，从而 确定潜在的疾病改良目标。

PROJECT SUMMARY The overall objective of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to exploit signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. To do this, C-SiG provides a robust infrastructure, thematic platforms, and career development opportunities to integrate and amplify impactful investigation along the discovery-translation-application paradigm. Our Research Base now consists of 68 scientists (15% growth) involving 18 departments and $23.7 million (direct costs, 2.5% growth) in digestive disease-related funding. Responding to members' evolving interests and scientific advances, we've re-aligned members into three interconnected Mechanistic Research Themes (intracellular signaling, cell-to-cell communication, and genetics/epigenetics), each intersecting with three Disease Focus Groups (liver pathobiology, enteric neurosciences, inflammation/transformation), a matrix that fosters both discovery and disease relevant investigation. Our ongoing CENTRAL HYPOTHESIS is that advances in care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful interactions among multidisciplinary scientists investigating cellular mechanisms, pathways, and therapeutic targets to enhance rapid translation of basic discoveries into clinical trials. Our OVERALL SPECIFIC AIMS are to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established GI scientists and attracting investigators from other disciplines; ii) Identify and nurture new GI investigators via a peer-reviewed Pilot and Feasibility (P/F) Program including career development workshops, curricula, and structured mentorship (19/26, 73% of P/F recipients achieving federal funding); iii) Offer core-based specialized equipment, technologies, methodologies, reagents, and expertise (Optical Microscopy, Clinical, and Gene Editing and Epigenomics Cores), with continuous core menu updates, quality assurance and assessments, and project management oversight in response to member feedback; iv) Support a robust Enrichment Program; and v) Promote interactions between C-SiG with other NIDDK centers at Mayo (e.g., PKD Center) and existing DDRCCs, especially in the Midwest (i.e., Midwest DDRCC Alliance). Our global efforts have resulted in 215 manuscripts, with 56% percent intra- and 44% inter-thematic publications (70% involving two or more members). Importantly, we've made critical advances in understanding disease pathogenesis relevant to signal transduction, cell-to-cell communication and genetics/epigenetics, thereby identifying potential disease modifying targets.